INTRODUCTION: This study sought to test the association between 3,4-methylenedioxymethamphetamine use, serotonergic function and sleep. MATERIALS AND METHODS:Ambulatory polysomnography was used to measure three nights sleep in 12 ecstasy users and 12 controls after screening (no intervention), atryptophan-free amino acid mixture (acute tryptophan depletion (ATD)) and a tryptophan-supplemented control mixture. RESULTS: ATD significantly decreased rapid eye movement (REM) sleep onset latency, increased the amount of REM sleep and increased the amount of stage 2 sleep in the first 3 h of sleep. There was no difference between ecstasy users' and controls' sleep on the screening night or after ATD. DISCUSSION: These findings imply that the ecstasy users had not suffered significant serotonergic damage as indexed by sleep.
RCT Entities:
INTRODUCTION: This study sought to test the association between 3,4-methylenedioxymethamphetamine use, serotonergic function and sleep. MATERIALS AND METHODS: Ambulatory polysomnography was used to measure three nights sleep in 12 ecstasy users and 12 controls after screening (no intervention), a tryptophan-free amino acid mixture (acute tryptophan depletion (ATD)) and a tryptophan-supplemented control mixture. RESULTS: ATD significantly decreased rapid eye movement (REM) sleep onset latency, increased the amount of REM sleep and increased the amount of stage 2 sleep in the first 3 h of sleep. There was no difference between ecstasy users' and controls' sleep on the screening night or after ATD. DISCUSSION: These findings imply that the ecstasy users had not suffered significant serotonergic damage as indexed by sleep.
Authors: Ari D Kalechstein; Richard De La Garza; James J Mahoney; William E Fantegrossi; Thomas F Newton Journal: Psychopharmacology (Berl) Date: 2006-11-03 Impact factor: 4.530
Authors: U Scheffel; Z Szabo; W B Mathews; P A Finley; R F Dannals; H T Ravert; K Szabo; J Yuan; G A Ricaurte Journal: Synapse Date: 1998-06 Impact factor: 2.562
Authors: Linda Booij; Willem Van der Does; Chawki Benkelfat; J Douglas Bremner; Philip J Cowen; Maurizio Fava; Christian Gillin; Marco Leyton; Polly Moore; Katharine A Smith; Willem A Van der Kloot Journal: Neuropsychopharmacology Date: 2002-11 Impact factor: 7.853
Authors: Simon N Young; Martine Regoli; Marco Leyton; Robert O Pihl; Chawki Benkelfat Journal: Psychopharmacology (Berl) Date: 2013-10-19 Impact factor: 4.530